Takeda is supporting the BLA with data from the pivotal VISIBLE 2 Phase III trial, in which 409 adult patients experienced a clinical responsedefined as a decrease of 70 points or more in Crohns Disease Activity Index (CDAI) score from baselinefollowing two doses of open-label IV Entyvio
Overall, GLP-1 receptor agonists appear most beneficial for cardiometabolic risk reduction, obesity management, and prevention of atherosclerotic cardiovascular events
While this study into weight loss jabs is important and promising, we believe such medications are only a short-term solution
According to the Mayo Clinic, many believe the diet works (what works means is also up for debate) because our genes are not well adjusted for modern diets that grew out of farming. Thats not accurate, but weight loss is often billed as proof of the theory
Evidence shows that GLP-1 has the effect of slowing down the gastrointestinal tract, meaning food takes longer to empty from the stomach
It must be injected because peptides are broken down by stomach acid